30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice

Journal of Clinical Psychopharmacology

Volumn 29, Issue 6, 2009, Pages 576-583

  Coccurello, Roberto ^a,b   Brina, Daniela ^c   Caprioli, Antonio ^b   Conti, Roberto ^b   Ghirardi, Orlando ^b   Schepis, Filippo ^c   Moles, Anna ^a  

^a CNR   (Italy)

^b Sigma Tau SpA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Energy expenditure; Leptin resistance; Metabolic syndrome; OGTT; Olanzapine

Indexed keywords

FAT; GLUCOSE; INSULIN; LEPTIN; OLANZAPINE; UNCLASSIFIED DRUG; VELOTAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CALORIMETRY; CHRONIC DRUG ADMINISTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG INFUSION; DYSLIPIDEMIA; ENERGY EXPENDITURE; FAT CONTENT; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HORMONE BLOOD LEVEL; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERPHAGIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID STORAGE; LIVER HISTOLOGY; LUNG GAS EXCHANGE; METABOLIC DISORDER; METABOLIC RATE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OSMOTIC MINIPUMP; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; WEIGHT GAIN;

ANIMALS; BENZODIAZEPINES; BODY WEIGHT; DYSLIPIDEMIAS; ENERGY METABOLISM; FEMALE; GLUCOSE INTOLERANCE; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICE; TIME FACTORS;

EID: 72949088255     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181bfe13e     Document Type: Article

References (37)

1. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;1:1-93.
2. Baptista T, Zarate J, Joober R, et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets. 2004;5:279-299.
3. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry. 2001;62:4-10.
4. Baptista T, ElFakih Y, Uzcátegui E, et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs. 2008;22:477-495.
5. 2 dopamine receptors involved? Pharmacol Biochem Behav. 1987;27:399-405.
6. Baptista T, Lacruz A, Pàez X, et al. The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? Eur J Pharmacol. 2002;447:91-98.
7. Cope MB, Nagy TR, Fernández JR, et al. Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes. 2005;29: 607-614.
8. Baptista T, Araujo de Baptista E, Ying Kin NM, et al. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: Body weight, food intake, body composition, hormones and glucose tolerance. Brain Res. 2002;957:144-151.
9. Cooper GD, Harrold JA, Halford JC, et al. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:428-436.
10. Sondhi S, Castellano JM, Chong VZ, et al. cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drugYinduced adverse metabolic effects. Pharmacogenomics J. 2006;6:131-140.
11. Goudie AJ, Smith JA, Halford JC. Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol. 2002;16:291-296.
12. Fell MJ, Marshall KM, Williams J, et al. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol. 2004;18:149-155.
13. Cooper GD, Pickavance LC, Wilding JP, et al. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology. 2005;181:80-89.
14. Coccurello R, Caprioli A, Ghirardi O, et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology. 2006;186:561-571.
15. Coccurello R, Caprioli A, Conti R, et al. Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3] benzothiazepine), chronic administration induces weight gain, hyperphagia, and metabolic dysregulation in mice. J Pharmacol Exp Ther. 2008;326:905-911.
16. Coccurello R, D-Amato FR, Moles A. Chronic administration of olanzapine affects behavioural satiety sequence and feeding behaviour in female mice. Eat Weight Disord. 2008;13:55-60.
17. Kapur S, VanderSpek SC, Brownlee BA, et al. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther. 2003;305:625-631.
18. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
19. Ruxton GD, Beauchamp G. Time for some a priori thinking about post hoc testing. Behav Ecol. 2008;19:690-693.
20. Wilcox RR. New Statistical Procedures for the Social Sciences. Modern Solutions to Basic Problems. Hillsdale, NJ: Lawrence Erlbaum; 1987.
21. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 2005;162:118-123.
22. Stefanidis A, Verty AN, Allen AM, et al. The role of thermogenesis in antipsychotic drugYinduced weight gain. Obesity. 2009;17:16-24.
23. Sharpe JK, Byrne NM, Stedman TJ, et al. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc. 2005;105:612-615.
24. Virkkunen M, Wahlbeck K, Rissanen A, et al. Decrease of energy expenditure causes weight increase in olanzapine treatmentVa case study. Pharmacopsychiatry. 2002;35:124-126.
25. Tsuda K, Yoshimatsu H, Niijima A, et al. Hypothalamic histamine neurons activate lipolysis in rat adipose tissue. Exp Biol Med. 2002;227:208-213.
26. Bymaster FP, Nelson DL, DeLapp NW, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999;37:107-122.
27. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
28. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519-526.
29. Banks WA. Enhanced leptin transport across the blood-brain barrier by alpha 1-adrenergic agents. Brain Res. 2001;899:209-217.
30. Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2005;67:789-797.
31. Houseknecht KL, Robertson AS, Zawadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:282-297.
32. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav. 2003;75:255-260.
33. Choi S, DiSilvio B, Unangst J, et al. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci. 2007;81:1024-1030.
34. Lykkegaard K, Larsen PJ, Vrang N, et al. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res. 2008;103:94-103.
35. Chintoh AF, Mann SW, Lam TK, et al. Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophr Res. 2008;104:23-30.
36. Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005;57:406-411.
37. van der Zwaal EM, Luijendijk MC, Adan RA, et al. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol. 2008;585:130-136.